Back to all press releases New York, NY – October 5, 2022 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on TALEN®-edited smart CAR T-cel
Early intervention is probably the most influential element in the prevention and treatment of tumour growth and cancers. Through the use of markers, we can quickly and easily obtain important preliminary information to detect tumours and treat them before they cause significant harm to a patient. Today, rapid advancements in medical science have identified a multitude of markers and are.